Investegate announcements from 4Bio Capital, 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
4Bio Capital
4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round
4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round
Press Release
1 March 2021
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced it has become an investor in CARISMA Therapeutics, a biopharmaceutical company focused on discovering and developing innovative immunotherapies.
4BIO participated in the second closing of CARISMA’s $59 million Series B round, alongside founding investors IP Group, Inc. and Penn Medicine, joining the initial Series B investor syndicate of SymBiosis II, Solasta Ventures, Livzon Pharmaceuticals Group, AbbVie Ventures, HealthCap, Wellington Partners, TPG Biotech, Agent Capital and MRL Venture Fund.
sarno just couldn t get this song out of his head. musicologist began searching for the source of these captivating sounds. deep in the rain forest in central africa. the bio capital. that man famously ellis and the likes of an imbecile is a valuable thug left in the enemy one. million living costs he was fascinated by their culture and that he stayed. only a promise to our son was a bit sorry of the jungle and returned to the concrete and glass john. the result